Welcome
Support Centre
20 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
HERA: A randomised three-arm multi-centre comparison of 1 year and 2-years of Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy
ISRCTN ISRCTN82811952
ClinicalTrials.gov identifier
Public title HERA: A randomised three-arm multi-centre comparison of 1 year and 2-years of Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy
Scientific title
Acronym HERA
Serial number at source N/A
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast
Participants - inclusion criteria 1. Females aged ≥18 years
2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
3. Non-metastatic operable primary invasive adenocarcinoma of the breast that is histologically confirmed, adequately excised and axillary node positive or negative
4. Known hormone receptor status
5. Completion of at least 3 months of an approved (neo-) adjuvant chemotherapy regimen
6. Baseline left ventricular ejection fraction (LVEF) ≥55%
7. Completion of radiotherapy for any patients undergoing radiotherapy
8. Overexpression of HER2 in the invasive component of the primary tumour
9. Completion of all necessary baseline lab and radiological investigations
10. Signed written informed consent
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/03/2002
Anticipated end date 01/12/2004
Status of trial Completed
Patient information material
Target number of participants 3192
Interventions 1. Patients are randomised to receive Herceptin every 3 weeks for 1 or 2 years
2. No further treatment
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Roche Products Ltd
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Roche Products Limited (UK)
  Address P.O. Box 8
  City/town Welwyn Garden City, Hertfordshire
  Zip/Postcode AL7 3AY
  Country United Kingdom
  Tel +44(0)1707 366000
  Fax +44(0)1707 338297
  Email
  Sponsor website: http://www.roche.com
Date applied 15/10/2002
Last edited 21/11/2005
Date ISRCTN assigned 15/10/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central